• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非诺贝特和选择性过氧化物酶体增殖物激活受体 α 调节剂(SPPARMa)、帕马溴对 KATP 通道活性和胰岛素分泌的影响。

Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion.

机构信息

Department of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Department of Plastic and Reconstructive Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

出版信息

BMC Res Notes. 2023 Sep 11;16(1):202. doi: 10.1186/s13104-023-06489-7.

DOI:10.1186/s13104-023-06489-7
PMID:37697384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10494450/
Abstract

OBJECTIVE

Insulin secretion is regulated by ATP-sensitive potassium (K) channels in pancreatic beta-cells. Peroxisome proliferator-activated receptors (PPAR) α ligands are clinically used to treat dyslipidemia. A PPARα ligand, fenofibrate, and PPARγ ligands troglitazone and 15-deoxy-∆-prostaglandin J2 are known to close K channels and induce insulin secretion. The recently developed PPARα ligand, pemafibrate, became a new entry for treating dyslipidemia. Because pemafibrate is reported to improve glucose intolerance in mice treated with a high fat diet and a novel selective PPARα modulator, it may affect K channels or insulin secretion.

RESULTS

The effect of fenofibrate (100 µM) and pemafibrate (100 µM) on insulin secretion from MIN6 cells was measured by using batch incubation for 10 and 60 min in low (2 mM) and high (10 mM) glucose conditions. The application of fenofibrate for 10 min significantly increased insulin secretion in low glucose conditions. Pemafibrate failed to increase insulin secretion in all of the conditions experimented in this study. The K channel activity was measured by using whole-cell patch clamp technique. Although fenofibrate (100 µM) reduced the K channel current, the same concentration of pemafibrate had no effect. Both fenofibrate and pemafibrate had no effect on insulin mRNA expression.

摘要

目的

胰岛素分泌受胰腺β细胞中三磷酸腺苷敏感性钾(K)通道的调节。过氧化物酶体增殖物激活受体(PPAR)α配体临床上用于治疗血脂异常。PPARα配体非诺贝特、PPARγ配体曲格列酮和 15-去氧-Δ-前列腺素 J2 已知可关闭 K 通道并诱导胰岛素分泌。最近开发的 PPARα 配体 pemafibrate 已成为治疗血脂异常的新选择。由于报道称 pemafibrate 可改善高脂肪饮食和新型选择性 PPARα调节剂治疗的小鼠的葡萄糖不耐受,因此它可能会影响 K 通道或胰岛素分泌。

结果

通过批孵育 10 和 60 分钟,在低(2 mM)和高(10 mM)葡萄糖条件下,测量了非诺贝特(100 μM)和 pemafibrate(100 μM)对 MIN6 细胞胰岛素分泌的影响。非诺贝特孵育 10 分钟可显著增加低葡萄糖条件下的胰岛素分泌。在本研究中实验的所有条件下,pemafibrate 均未能增加胰岛素分泌。通过全细胞膜片钳技术测量 K 通道活性。虽然非诺贝特(100 μM)降低了 K 通道电流,但相同浓度的 pemafibrate 没有作用。非诺贝特和 pemafibrate 对胰岛素 mRNA 表达均没有影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c9f/10494450/6f90d7941b60/13104_2023_6489_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c9f/10494450/aef7dd3ca9ba/13104_2023_6489_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c9f/10494450/bf72e48c182e/13104_2023_6489_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c9f/10494450/d6f347d322f2/13104_2023_6489_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c9f/10494450/6f90d7941b60/13104_2023_6489_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c9f/10494450/aef7dd3ca9ba/13104_2023_6489_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c9f/10494450/bf72e48c182e/13104_2023_6489_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c9f/10494450/d6f347d322f2/13104_2023_6489_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c9f/10494450/6f90d7941b60/13104_2023_6489_Fig4_HTML.jpg

相似文献

1
Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion.非诺贝特和选择性过氧化物酶体增殖物激活受体 α 调节剂(SPPARMa)、帕马溴对 KATP 通道活性和胰岛素分泌的影响。
BMC Res Notes. 2023 Sep 11;16(1):202. doi: 10.1186/s13104-023-06489-7.
2
Fenofibrate, troglitazone, and 15-deoxy-Delta12,14-prostaglandin J2 close KATP channels and induce insulin secretion.非诺贝特、曲格列酮和15-脱氧-Δ12,14-前列腺素J2可关闭ATP敏感性钾通道并诱导胰岛素分泌。
J Pharmacol Exp Ther. 2004 Sep;310(3):1273-80. doi: 10.1124/jpet.104.067249. Epub 2004 Jun 16.
3
Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα.过氧化物酶体增殖物激活受体 α(PPARα)及其新型特异高效配体非诺贝特的分子缔合模型:SPPARMα 的结构基础。
Biochem Biophys Res Commun. 2018 May 5;499(2):239-245. doi: 10.1016/j.bbrc.2018.03.135. Epub 2018 Mar 22.
4
The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice.过氧化物酶体增殖物激活受体 α(PPARα)激动剂 pemafibrate 可预防小鼠饮食诱导的肥胖。
Int J Mol Sci. 2018 Jul 23;19(7):2148. doi: 10.3390/ijms19072148.
5
Pemafibrate, a selective PPARα modulator, and fenofibrate suppress microglial activation through distinct PPARα and SIRT1-dependent pathways.非诺贝特,一种选择性过氧化物酶体增殖物激活受体α调节剂,通过不同的过氧化物酶体增殖物激活受体α和 SIRT1 依赖途径抑制小胶质细胞的激活。
Biochem Biophys Res Commun. 2020 Apr 2;524(2):385-391. doi: 10.1016/j.bbrc.2020.01.118. Epub 2020 Jan 29.
6
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.贝特类药物在血脂异常患者中的疗效和安全性:一项为期 24 周、随机、双盲、阳性对照、3 期临床试验的结果。
J Clin Lipidol. 2018 Jan-Feb;12(1):173-184. doi: 10.1016/j.jacl.2017.10.006. Epub 2017 Oct 28.
7
Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.非诺贝特,一种新型选择性过氧化物酶体增殖物激活受体 α 调节剂:药物概念及其在血脂异常和代谢性疾病中的临床应用。
Curr Atheroscler Rep. 2020 Jan 23;22(1):5. doi: 10.1007/s11883-020-0823-5.
8
The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.新型选择性过氧化物酶体增殖物激活受体α调节剂(SPPARMα)匹伐他汀可改善血脂异常,增强胆固醇逆向转运,并减轻炎症和动脉粥样硬化。
Atherosclerosis. 2016 Jun;249:200-8. doi: 10.1016/j.atherosclerosis.2016.03.003. Epub 2016 Mar 4.
9
Elucidation of Molecular Mechanism of a Selective PPARα Modulator, Pemafibrate, through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations.通过 X 射线晶体学、热力学分析和第一性原理计算的组合方法阐明选择性过氧化物酶体增殖物激活受体α调节剂 pemafibrate 的分子机制。
Int J Mol Sci. 2020 Jan 6;21(1):361. doi: 10.3390/ijms21010361.
10
A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.一种新型选择性过氧化物酶体增殖物激活受体α调节剂(SPPARMα),K-877(非诺贝特),可减轻小鼠餐后高甘油三酯血症。
J Atheroscler Thromb. 2018 Feb 1;25(2):142-152. doi: 10.5551/jat.39693. Epub 2017 Aug 5.

本文引用的文献

1
Association of modifiable risk factors with ischaemic stroke subtypes in Asian versus Caucasian populations: A systematic review and meta-analysis.亚洲人群与高加索人群中可改变的风险因素与缺血性卒中亚型的相关性:系统评价和荟萃分析。
Eur J Clin Invest. 2022 Nov;52(11):e13849. doi: 10.1111/eci.13849. Epub 2022 Aug 5.
2
PPAR control of metabolism and cardiovascular functions.过氧化物酶体增殖物激活受体(PPAR)对代谢和心血管功能的调控。
Nat Rev Cardiol. 2021 Dec;18(12):809-823. doi: 10.1038/s41569-021-00569-6. Epub 2021 Jun 14.
3
New insights into K channel gene mutations and neonatal diabetes mellitus.
钾通道基因突变与新生儿糖尿病的新见解。
Nat Rev Endocrinol. 2020 Jul;16(7):378-393. doi: 10.1038/s41574-020-0351-y. Epub 2020 May 6.
4
Mechanism of pharmacochaperoning in a mammalian K channel revealed by cryo-EM.冷冻电镜解析哺乳动物 K 通道的药理学伴侣作用机制。
Elife. 2019 Jul 25;8:e46417. doi: 10.7554/eLife.46417.
5
Selective peroxisome proliferator-activated receptor-α modulator K-877 regulates the expression of ATP-binding cassette transporter A1 in pancreatic beta cells.过氧化物酶体增殖物激活受体-α调节剂 K-877 调节胰岛β细胞中 ATP 结合盒转运体 A1 的表达。
Eur J Pharmacol. 2018 Nov 5;838:78-84. doi: 10.1016/j.ejphar.2018.09.015. Epub 2018 Sep 7.
6
Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia.非诺贝特(K-877),一种新型的选择性过氧化物酶体增殖物激活受体α调节剂,用于治疗动脉粥样硬化性血脂异常。
Cardiovasc Diabetol. 2017 Oct 4;16(1):124. doi: 10.1186/s12933-017-0602-y.
7
K Channel Mutations and Neonatal Diabetes.钾通道突变与新生儿糖尿病
Intern Med. 2017 Sep 15;56(18):2387-2393. doi: 10.2169/internalmedicine.8454-16. Epub 2017 Aug 21.
8
Nesfatin-1 inhibits voltage gated K channels in pancreatic beta cells.内脂素-1抑制胰腺β细胞中的电压门控钾通道。
Peptides. 2017 Sep;95:10-15. doi: 10.1016/j.peptides.2017.07.001. Epub 2017 Jul 8.
9
Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway.新型选择性PPARα调节剂K-877对db/db小鼠的肾脏保护作用:二酰甘油-蛋白激酶C-NAD(P)H氧化酶途径的作用
Metabolism. 2017 Jun;71:33-45. doi: 10.1016/j.metabol.2017.02.013. Epub 2017 Mar 3.
10
Fenofibrate Decreases Insulin Clearance and Insulin Secretion to Maintain Insulin Sensitivity.非诺贝特降低胰岛素清除率和胰岛素分泌以维持胰岛素敏感性。
J Biol Chem. 2016 Nov 11;291(46):23915-23924. doi: 10.1074/jbc.M116.745778. Epub 2016 Sep 23.